BeOne Medicines AG (HKG:6160)
251.80
-0.40 (-0.16%)
Nov 11, 2026, 4:08 PM HKT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.89B USD in the quarter ending September 30, 2026, with 33.81% growth. This brings the company's total for the last twelve months to $6.61B, up 32.86% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth. That makes BeOne Medicines AG the 2,167th largest company in the world by revenue and 148th in Hong Kong.
Revenue (ttm)
$6.61B
Revenue Growth
+32.86%
P/S Ratio
7.51
Revenue / Employee
$550.54K
Employees
12,000
Market Cap
379.35B HKD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BeOne Medicines AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | 173.79M | 711.45% |
| Dec 31, 2017 | 24.43M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 38.91B |
| WuXi Biologics | 27.27B |
| 3SBio | 20.63B |
| Innovent Biologics | 18.13B |
| RemeGen | 9.70B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| Akeso | 3.98B |
BeOne Medicines AG News
- 4 days ago - BeOne Medicines price target raised to $477 from $454 at TD Cowen - TheFly
- 4 days ago - BeOne Medicines price target raised to $465 from $425 at Morgan Stanley - TheFly
- 4 days ago - BeOne Medicines Q3 Earnings Call Highlights - MarketBeat
- 4 days ago - BeOne Medicines price target raised to $448 from $420 at Truist - TheFly
- 4 days ago - BeOne Medicines price target raised to $463 from $405 at Citizens - TheFly
- 4 days ago - BeOne Medicines price target raised to $446 from $415 at Barclays - TheFly
- 5 days ago - Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics - Nasdaq
- 5 days ago - BeOne Medicines (ONC) Q3 2026 Earnings Call Transcript - The Motley Fool